494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |